Search / Trial NCT00000126

Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)

Launched by NATIONAL EYE INSTITUTE (NEI) · Sep 23, 1999

Apply for Trial

Trial Information

Current as of December 10, 2023

Unknown status

Keywords

Non Arteritic Ischemic Optic Neuropathy

Description

NAION is the most common cause of acute optic nerve disease in the elderly, causing permanent and severe visual loss. No proven treatment currently exists to reverse or arrest this loss. There is no accepted method for the prevention or reduction of the likelihood of second eye involvement. NAION strikes both eyes in as many as 40 percent of affected patients (Beri et al. 1987), with a 2-year risk of about 25 percent (Steven Feldon, personal communication to SEK). IONDT compared optic nerve decompression surgery (ONDS), which was becoming a widely used treatment for NAION, with careful fol...

Gender

All

Eligibility criteria

  • All living patients from the 420 patients originally enrolled in the IONDT have been asked to participate in the IONDT Followup Study. No new patients are being recruited.

Attachments

readout_NCT00000126_2023-12-10.pdf

4.5 MB

NCT00000126_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Rochester, Minnesota, United States

Los Angeles, California, United States

Los Angeles, California, United States

San Francisco, California, United States

Gainesville, Florida, United States

Atlanta, Georgia, United States

Chicago, Illinois, United States

Lexington, Kentucky, United States

Baltimore, Maryland, United States

Ann Arbor, Michigan, United States

East Lansing, Michigan, United States

Royal Oak, Michigan, United States

Columbia, Missouri, United States

St. Louis, Missouri, United States

Syracuse, New York, United States

Charlotte, North Carolina, United States

Cleveland, Ohio, United States

Pittsburgh, Pennsylvania, United States

Columbia, South Carolina, United States

Houston, Texas, United States

Salt Lake City, Utah, United States

Charlottesville, Virginia, United States

Richmond, Virginia, United States

Morgantown, West Virginia, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0